Diagonal Bio AB ("Diagonal Bio") has received conditional approval for listing on Nordic SME at Nordic Growth Market. The first trading day is expected to be March 19, 2025.
Diagonal Bio operates in the biotechnology sector. The Company develops a platform under the name Panviral, designed to detect and diagnose small sections of pathogen genomes, including those of viruses, bacteria, and fungi. In addition to its core business, the Company also provides related services and support offerings. Diagonal Bio primarily operates in Sweden and is headquartered in Lund.
The listing decision is conditional upon the company meeting the listing requirement that no new information emerges which would affect the company's compliance with the listing requirements.
Shareholders in Diagonal Bio will not need to take any action in connection with the change of marketplace.
Learn more about Diagonal Bio at www.diagonalbio.com
For further information, please contact:
The Listing Department, Nordic Growth Market, notering@ngm.se
Carl-Henrik Nordberg, Head of Equity, Nordic Growth Market, carl-henrik.nordberg@ngm.se
